Direct Antiglobulin (Direct Coombs) Test
The direct antiglobulin test (DAT) is a simple test used to determine if red cells have been coated in vivo with immunoglobulin, complement, or both. The direct antiglobulin test looks for antibodies attached to red blood cell antigens (RBCs). DAT testing can be requested for many of the following reasons:
- It is used in evaluation of newborns born to Blood Group O mothers to determine the risk for increased bilirubin symptoms due to ABO incompatibility or for newborns known to be at risk for Hemolytic Disease of the Fetus and Newborn (HDFN).
- DAT testing may be indicated for investigating a positive antibody screen. Pan-reactivity seen in antibody screens can be the first indication of a patient presenting with positive DAT complications. Resolving these investigations and finding compatible units of blood for transfusion poses transfusion medicine some of its most complicated cases.
- It is used in the evaluation of hemolytic anemias. Patients with warm autoantibodies usually have a positive DAT and shortened red blood call survival. In these cases a further evaluation of the positive DAT should be performed to identify whether the positive test is caused by IgG alone, IgG and complement, or complement alone. These autoantibodies may be produced in autoimmune diseases and with some other conditions, such as lymphoma, chronic lymphocytic leukemia, or viruses. Sometimes, drugs may coat the surface of RBCs, causing a positive DAT test.
- When investigating a possible transfusion reaction, performance of the DAT on post-reaction specimens is part of the initial investigation. The DAT may be positive. This is true only if sensitized red cells have not been destroyed and cleared by the spleen. If post-infusion sample testing shows a positive DAT, the initial pre-transfusion specimen should be tested to aid in determining infusion complications.
- As an aid in diagnosis of hemolytic anemia in autoimmune diseases such as systemic lupus erythematosus
- As an aid in diagnosis of hemolytic anemia in malignant diseases such as lymphoma and chronic lymphocytic leukemia
- As an aid in diagnosis of hemolytic anemia in infections such as mycoplasma pneumonia and mononucleosis
- In diagnosis of drug-induced hemolytic anemia
- To help diagnose hemolytic disease of the fetus and newborn (HDFN)
- Pre-transfusion screening, to assist in evaluating positive antibody screens and identifications
Positive in:
- Autoantibodies to intrinsic red cell antigens
- Hemolytic transfusion reactions
- Hemolytic disease of the fetus and newborn
- Drug-induced antibodies and passively acquired alloantibodies (e.g., donor plasma, derivatives, immunoglobulin)
- Nonspecifically adsorbed proteins (hypergammaglobulinemia, high-dose intravenous immune globulin, modification of red cell membranes by some drugs)
- Complement activation due to bacterial infection
- Auto or alloantibodies, autoimmune hemolytic anemia
- Alloimmune reactions to recently transfused cells, and drug-induced hemolysis
Note: A positive DAT alone is not diagnostic; the interpretation of the significance of this positive result requires knowledge of the patient’s diagnosis. Clinical considerations together with laboratory data should dictate the extent to which a positive DAT is evaluated.
Negative (Not detected)
Antigen-Antibody Reaction, Hemagglutination, Immune diffusion (gel)
Whole Blood EDTA (Lavender or Pink) ACD (Yellow).
Stability
- Ambient: 48 hours
- Refrigerated: 72 hours
- Frozen: Unacceptable
If a DAT is positive, further testing should be performed with specific reagents to determine the types of protein(s) coating the red cells. Additional tests useful in classifying the hemolytic anemia and procedures for detecting alloantibodies in the presence of autoantibodies are defined as eluate testing. Chemistry (bilirubin) and hematology (RBC, and hemoglobin testing) can provide additional information to determine the severity of red cell destruction. Results of these tests combined with the patient’s history and clinical data should assist in classification of the problem involved. Patient red cell antigen phenotyping. Red cell Autoabsorption. Coombs phase crossmatch.
Usually same day
- Technical Manual of the American Association of Blood Banks, 16th ed. American Association of Blood Banks, 2008.
- J Gynecol Obstet Biol Reprod (Paris). 2004 Nov;33(7):637-48. [PMID: 15550883]
- Transfusion. 2007 May;47(5):911-7. [PMID: 17465958]
- Am J Hematol. 2013 Feb;88(2):93-6. [PMID: 23169533]